logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q4 2019
Forty Seven, Inc.
Data from Phase 1b trial of 5F9 in combination with avelumab
Ovarian cancer
Q4 2019
Sesen Bio Inc
Submission of BLA for Vicinium
High-grade non-muscle invasive bladder cancer
Q4 2019
Achillion Pharmaceuticals Inc.
Submission of IND application for ACH-5228
Multiple diseases
Q4 2019
Regeneron Pharmaceuticals
Filing of sBLA for Dupixent
Severe atopic dermatitis in children
Q4 2019
Sanofi
Filing of sBLA for Dupixent
Severe atopic dermatitis in children
Q4 2019
Paratek Pharmaceuticals, Inc.
Topline data from phase II studies of NUZYRA
Urinary tract infections
Q4 2019
Autolus Therapeutics plc
Interim data from phase I trial of AUTO3
Diffuse large B-cell lymphoma (DLBCL)
12-Sep-2019
Adverum Biotechnologies Inc.
24-week interim data from phase I study of intravitreal gene therapy with ADVM-022(OPTIC)
Neovascular (Wet) Age-Related Macular Degeneration
after Q4 2019
Atreca Inc.
Filing of IND application for ATRC-101
Solid tumors
after Q4 2019
Morphic Holding Inc.
Submission of IND for MORF-720
Idiopathic pulmonary fibrosis.
after Q4 2019
Corvus Pharmaceuticals, Inc.
Initial data from phase 1/1b study of CPI-818
T-cell lymphomas
after Q4 2019
Karyopharm Therapeutics Inc.
Top-line data from phase III study of Selinexor (BOSTON)
Triple class refractory multiple myeloma
after Q4 2019
CHIASMA, INC
Submission of NDA for MYCAPSSA
Adult patients with acromegaly
after Q4 2019
Oncolytics Biotech
ONC.TO, ONCY
Interim data from open-label window-of-opportunity study combining Pelareorep and Tecentriq (AWARE-1)
Early-stage breast cancer
after Q4 2019
Harpoon Therapeutics Inc.
Filing of IND for HPN217
Multiple myeloma
after Q4 2019
Progenics Pharmaceuticals Inc
Topline data from phase III trial of PyL(CONDOR)
Male patients with biochemical recurrence of prostate cancer
after Q4 2019
Acceleron Pharma, Inc
Results from phase II trial of Luspatercept
Myelofibrosis
after Q4 2019
VBI Vaccines Inc.
Top-line results from second pivotal Phase 3 study of Sci-B-Vac ( CONSTANT)
Hepatitis B
after Q4 2019
G1 Therapeutics, Inc.
Detailed data from phase II trial of Trilaciclib in combination with chemotherapy
Metastatic triple-negative breast cancer
after Q4 2019
PIERIS PHARMACEUTICALS, INC.
Comprehensive data from phase I dose-escalation study of PRS-343
HER2-positive solid tumors
after Q4 2019
PIERIS PHARMACEUTICALS, INC.
Filing of IND for PRS-344
PD-L1/4-1BB bispecific drug candidate being co-developed with Servier
after Q4 2019
Wave Life Sciences Ltd.
Topline data readout from Phase 1b/2a clinical trial of WVE-120101 (PRECISION-HD)
Huntington's disease
after Q4 2019
Wave Life Sciences Ltd.
Topline data readout from Phase 1b/2a clinical trial of WVE-120102 (PRECISION-HD)
Huntington's disease
after Q4 2019
STEALTH BIOTHERAPEUTICS CORP
Top-line data from phase III clinical trial of Elamipretide
Primary mitochondrial myopathy
after Q4 2019
Liquidia Technologies Inc.
Submission of NDA for LIQ861
Pulmonary arterial hypertension, or PAH